MUC16 and neoplasm: Changes in CA125 levels (GCIG criteria) were retrospectively compared with alterations in the tumour load (WHO criteria) during second-line chemotherapy with topotecan or paclitaxel–platinum in 124 consecutive patients with recurrent or refractory disease.